Commentary: Accessibility of cancer drugs in Switzerland: Time from approval to pricing decision between 2009 and 2018

Commentary: Accessibility of cancer drugs in Switzerland: Time from approval to pricing decision between 2009 and 2018

Bibliographic Details
Main Author: Thomas Grischott
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-09-01
Series:Frontiers in Public Health
Subjects:
cancer drugs
approval
reimbursement
price negotiation
health policy
public health
Online Access:https://www.frontiersin.org/article/10.3389/fpubh.2020.00517/full
id doaj-aa61ea339e6345b6b2de318f3fc0291e
record_format Article
spelling doaj-aa61ea339e6345b6b2de318f3fc0291e2020-11-25T03:43:29ZengFrontiers Media S.A.Frontiers in Public Health2296-25652020-09-01810.3389/fpubh.2020.00517563318Commentary: Accessibility of cancer drugs in Switzerland: Time from approval to pricing decision between 2009 and 2018Thomas Grischotthttps://www.frontiersin.org/article/10.3389/fpubh.2020.00517/fullcancer drugsapprovalreimbursementprice negotiationhealth policypublic health
collection DOAJ
language English
format Article
sources DOAJ
author Thomas Grischott
spellingShingle Thomas Grischott
Commentary: Accessibility of cancer drugs in Switzerland: Time from approval to pricing decision between 2009 and 2018
Frontiers in Public Health
cancer drugs
approval
reimbursement
price negotiation
health policy
public health
author_facet Thomas Grischott
author_sort Thomas Grischott
title Commentary: Accessibility of cancer drugs in Switzerland: Time from approval to pricing decision between 2009 and 2018
title_short Commentary: Accessibility of cancer drugs in Switzerland: Time from approval to pricing decision between 2009 and 2018
title_full Commentary: Accessibility of cancer drugs in Switzerland: Time from approval to pricing decision between 2009 and 2018
title_fullStr Commentary: Accessibility of cancer drugs in Switzerland: Time from approval to pricing decision between 2009 and 2018
title_full_unstemmed Commentary: Accessibility of cancer drugs in Switzerland: Time from approval to pricing decision between 2009 and 2018
title_sort commentary: accessibility of cancer drugs in switzerland: time from approval to pricing decision between 2009 and 2018
publisher Frontiers Media S.A.
series Frontiers in Public Health
issn 2296-2565
publishDate 2020-09-01
topic cancer drugs
approval
reimbursement
price negotiation
health policy
public health
url https://www.frontiersin.org/article/10.3389/fpubh.2020.00517/full
work_keys_str_mv AT thomasgrischott commentaryaccessibilityofcancerdrugsinswitzerlandtimefromapprovaltopricingdecisionbetween2009and2018
_version_ 1724519559839350784

Similar Items